NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD
0.6102
0 (-0.78%)
The current stock price of GBIO is 0.6102 USD. In the past month the price decreased by -36.66%. In the past year, price decreased by -71.08%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 174 full-time employees. The company went IPO on 2020-06-12. The firm is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The firm is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The firm is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
GENERATION BIO CO
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Geoff McDonough
Employees: 174
Company Website: https://generationbio.com/
Investor Relations: https://investors.generationbio.com/
Phone: 18575295908
The current stock price of GBIO is 0.6102 USD. The price decreased by -0.78% in the last trading session.
The exchange symbol of GENERATION BIO CO is GBIO and it is listed on the Nasdaq exchange.
GBIO stock is listed on the Nasdaq exchange.
13 analysts have analysed GBIO and the average price target is 7.14 USD. This implies a price increase of 1070.11% is expected in the next year compared to the current price of 0.6102. Check the GENERATION BIO CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENERATION BIO CO (GBIO) has a market capitalization of 40.76M USD. This makes GBIO a Nano Cap stock.
GENERATION BIO CO (GBIO) currently has 174 employees.
GENERATION BIO CO (GBIO) has a resistance level at 0.7. Check the full technical report for a detailed analysis of GBIO support and resistance levels.
The Revenue of GENERATION BIO CO (GBIO) is expected to grow by 370.54% in the next year. Check the estimates tab for more information on the GBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GBIO does not pay a dividend.
GENERATION BIO CO (GBIO) will report earnings on 2025-05-12, after the market close.
GENERATION BIO CO (GBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.19).
The outstanding short interest for GENERATION BIO CO (GBIO) is 4.05% of its float. Check the ownership tab for more information on the GBIO short interest.
ChartMill assigns a fundamental rating of 3 / 10 to GBIO. GBIO has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -10.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -58.47% | ||
ROE | -139.28% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to GBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 4.39% and a revenue growth 370.54% for GBIO